Details of the Drug

General Information of Drug (ID: DMLMIGI)

Drug Name

Belcesiran

Indication

Disease Entry	ICD 11	Status	REF
Alpha-1 antitrypsin deficiency	5C5A	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

RNA interference

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SERPINA1 messenger RNA (SERPINA1 mRNA)	TT2L4TV	A1AT_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04764448) A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Dicerna Pharmaceuticals